Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4700 alone or with pembrolizumab in advanced solid tumors
NCT06894771Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of MK-4700 in solid tumor (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicity at 21 days, Adverse Events at 4.5 years and 1 more. Started Apr 2025; status: completed.
02
Drugs
MK-4700
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06894771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06894771.